How many clinical-trial readouts are scheduled for January 2027?

pdufa.bio currently tracks 36 clinical-trial readouts with dates in January 2027, each linked to a primary source. The list updates as new filings appear and dates shift.

What is a clinical-trial readout date?

A readout date is the estimated time a trial reports topline results, based on its registered primary-completion date; these are estimates and shift.

Does pdufa.bio predict whether these will be approved?

No. We do not publish per-drug approval probabilities. We provide the verified facts, primary-source links, and historical base rates so you can judge for yourself.

pdufa.bio

Calendar Readouts Devices Decisions Approvals/yr Trial odds Learn Research Methodology

Home › Readouts › January 2027

January 2027 clinical-trial readouts

trial-readout estimates for January 2027, each row linked to its primary source. Readout dates are estimated primary-completion windows from ClinicalTrials.gov and shift.

← December 2026 February 2027 →

36 readouts

CGEM · Jan 2027 (est.)

CLN-081 — Relapsed/Refractory Acute Myeloid Leukemia (AML)

COYA · Jan 2027 (est.)

COYA 302 — Amyotrophic Lateral Sclerosis (ALS)

ELDN · Jan 2027 (est.)

Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapy — Prevention of Rejection in Kidney Transplant

ELVN · Jan 2027 (est.)

ELVN-002 — HER2-positive Breast Cancer

EXEL · Jan 2027 (est.)

Cabozantinib — Germ Cell Tumor

INAB · Jan 2027 (est.)

Autologous genetically modified gamma-delta T cells — Acute Myeloid Leukemia

IOVA · Jan 2027 (est.)

Lifileucel plus Pembrolizumab — Cervical Cancer

KURA · Jan 2027 (est.)

Ziftomenib — Solid Tumors With HRAS Alterations

KYTX · Jan 2027 (est.)

Standard of Care Treatment — ANCA-IgG-positive ANCA Associated Vasculitis

LRMR · Jan 2027 (est.)

CTI-1601 — Friedreich Ataxia

NRIX · Jan 2027 (est.)

NX-5948 — Chronic Lymphocytic Leukemia (CLL)

NUVL · Jan 2027 (est.)

Neladalkib — Locally Advanced Solid Tumor

PCVX · Jan 2027 (est.)

31-valent pneumococcal conjugate vaccine — Pneumococcal Vaccines

RARE · Jan 2027 (est.)

Setrusumab — Osteogenesis Imperfecta

SGMT · Jan 2027 (est.)

Denifanstat — Acne

SIGA · Jan 2027 (est.)

Tecovirimat Oral Capsule — Smallpox

XENE · Jan 2027 (est.)

Azetukalner — Major Depressive Disorder

ZVRA · Jan 2027 (est.)

KP415 oral capsule — Medium-chain Acyl-CoA Dehydrogenase Deficiency

ACAD · Jan 2027 (est.)

ACP-204 — Intermittent Explosive Disorder

CALC · Jan 2027 (est.)

CM4620 — Acute Pancreatitis

CADL · Jan 2027 (est.)

Aglatimagene Besadenovec — Malignant Glioma of Brain

BMY · Jan 2027 (est.)

Nivolumab — Hodgkin Lymphoma

REGN · Jan 2027 (est.)

Odronextamab — Follicular Lymphoma

OCUL · Jan 2027 (est.)

Otx-Tki — Neovascular Age-related Macular Degeneration

GILD · Jan 2027 (est.)

MK-3475 — Carcinoma, Non-Small-Cell Lung

AZTR · Jan 2027 (est.)

ATR04-484 — EGFR Inhibitor-associated Rash

IDYA · Jan 2027 (est.)

Darovasertib — Metastatic Uveal Melanoma

MLTX · Jan 2027 (est.)

Sonelokimab — Arthritis, Psoriatic

XBIT · Jan 2027 (est.)

Methotrexate — Rheumatoid Arthritis

CRBP · Jan 2027 (est.)

CRB-701 — Solid Tumor, Adult

SGMT · Jan 2027 (est.)

Denifanstat — Prostatic Neoplasms, Castration-Resistant

IDYA · Jan 2027 (est.)

IDE196 — Metastatic Uveal Melanoma

QNRX · Jan 2027 (est.)

QRX003 — Netherton Syndrome

CELZ · Jan 2027 (est.)

CELZ-201 Administration — Type 1 Diabetes

CUE · Jan 2027 (est.)

CUE-101 — Recurrent Glioblastoma

APLM · Jan 2027 (est.)

Uproleselan — Metastatic Non Small Cell Lung Cancer

Looking for an approval probability for these? We deliberately don't publish one — here's why, and what we show instead (verified history + base rates).